Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 675,111
  • Shares Outstanding, K 180,511
  • Annual Sales, $ 2,980 K
  • Annual Income, $ -195,880 K
  • EBIT $ -204 M
  • EBITDA $ -201 M
  • 60-Month Beta 2.69
  • Price/Sales 232.98
  • Price/Cash Flow N/A
  • Price/Book 4.29

Options Overview Details

View History
  • Implied Volatility 111.37% (-9.89%)
  • Historical Volatility 109.04%
  • IV Percentile 9%
  • IV Rank 3.85%
  • IV High 1,083.12% on 02/12/25
  • IV Low 72.45% on 02/11/25
  • Expected Move (DTE 11) 0.55 (13.35%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 2,493
  • Volume Avg (30-Day) 2,275
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 60,720
  • Open Int (30-Day) 59,736
  • Expected Range 3.59 to 4.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.20
  • Low Estimate -0.31
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +19.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.17 +32.02%
on 11/14/25
4.24 -1.27%
on 12/08/25
+0.38 (+9.84%)
since 11/07/25
3-Month
3.17 +32.02%
on 11/14/25
6.94 -39.70%
on 10/06/25
+0.29 (+7.58%)
since 09/08/25
52-Week
1.11 +277.03%
on 05/22/25
6.94 -39.70%
on 10/06/25
+0.91 (+27.98%)
since 12/06/24

Most Recent Stories

More News
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)
Prime Medicine to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --  -- Nominated PM647...

PRME : 4.23 (+13.10%)
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --  -- Nominated PM647...

PRME : 4.23 (+13.10%)
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)
Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)
Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?)

These two companies fit the type of transformative growth story Cathie Wood seeks out.

ARKW : 155.82 (unch)
ARKG : 31.19 (+0.84%)
RBRK : 89.19 (+3.38%)
PRME : 4.23 (+13.10%)
Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 4.23 (+13.10%)

Business Summary

Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.15
2nd Resistance Point 4.05
1st Resistance Point 3.89
Last Price 4.23
1st Support Level 3.63
2nd Support Level 3.53
3rd Support Level 3.38

See More

52-Week High 6.94
Fibonacci 61.8% 4.71
Last Price 4.23
Fibonacci 50% 4.03
Fibonacci 38.2% 3.34
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar